A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Saxagliptin (BMS-477118) in Combination With Metformin IR or Metformin XR in Pediatric Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01434186
Recruitment Status : Completed
First Posted : September 14, 2011
Results First Posted : April 18, 2017
Last Update Posted : April 18, 2017
Bristol-Myers Squibb
Information provided by (Responsible Party):

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: Double (Participant, Investigator);   Primary Purpose: Treatment
Condition: Diabetes Mellitus, Type 2
Interventions: Drug: Placebo matching with Saxagliptin
Drug: Metformin IR
Drug: Metformin XR
Drug: Saxagliptin

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
Of 32 subjects enrolled, 7 subjects entered the lead-in period. Of these 7 subjects, 6 were randomized

Reporting Groups
Placebo Placebo matching saxagliptin
Saxagliptin saxagliptin 2.5 or 5 mg according to body weight

Participant Flow:   Overall Study
    Placebo   Saxagliptin
STARTED   2   4 
COMPLETED   2   4 

  Baseline Characteristics

Population Description
Explanation of how the number of participants for analysis was determined. Includes whether analysis was per protocol, intention to treat, or another method. Also provides relevant details such as imputation technique, as appropriate.
No text entered.

Reporting Groups
Placebo Placebo matching saxagliptin
Saxagliptin saxagliptin 2.5 or 5 mg according to body weight
Total Total of all reporting groups

Baseline Measures
   Placebo   Saxagliptin   Total 
Overall Participants Analyzed 
[Units: Participants]
 2   4   6 
[Units: Participants]
Count of Participants
<=18 years      2 100.0%      4 100.0%      6 100.0% 
Between 18 and 65 years      0   0.0%      0   0.0%      0   0.0% 
>=65 years      0   0.0%      0   0.0%      0   0.0% 
Sex: Female, Male 
[Units: Participants]
Count of Participants
Female      2 100.0%      4 100.0%      6 100.0% 
Male      0   0.0%      0   0.0%      0   0.0% 

  Outcome Measures

1.  Primary:   Mean Change in HbA1c From Baseline to Week 16   [ Time Frame: 16 week short term treatment period ]

  Serious Adverse Events

  Other Adverse Events

  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.

  More Information

Certain Agreements:  
Principal Investigators are NOT employed by the organization sponsoring the study.
There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed.

Results Point of Contact:  
Name/Title: Eva Johnsson, Clinical Science Lead, GLOBAL_MEDICINES_DEV
Organization: AstraZeneca AB, S-151 85 Södertälje, Sweden
phone: +46 31 7762484 ext 762 484

Responsible Party: AstraZeneca Identifier: NCT01434186     History of Changes
Other Study ID Numbers: CV181-147
2010-024568-16 ( EudraCT Number )
First Submitted: September 13, 2011
First Posted: September 14, 2011
Results First Submitted: March 7, 2017
Results First Posted: April 18, 2017
Last Update Posted: April 18, 2017